Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder by Dittmann, Ralf W. et al.
                                                              
University of Dundee
Treatment response and remission in a double-blind, randomized, head-to-head study
of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with
attention-deficit hyperactivity disorder
Dittmann, Ralf W.; Cardo, Esther; Nagy, Peter; Anderson, Colleen S.; Adeyi, Ben; Caballero,
Beatriz; Hodgkins, Paul; Civil, Richard; Coghill, David R.
Published in:
CNS Drugs
DOI:
10.1007/s40263-014-0188-9
Publication date:
2014
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Dittmann, R. W., Cardo, E., Nagy, P., Anderson, C. S., Adeyi, B., Caballero, B., ... Coghill, D. R. (2014).
Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine
dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs,
28(11), 1059-1069. 10.1007/s40263-014-0188-9
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
ORIGINAL RESEARCH ARTICLE
Treatment Response and Remission in a Double-Blind,
Randomized, Head-to-Head Study of Lisdexamfetamine
Dimesylate and Atomoxetine in Children and Adolescents
with Attention-Deficit Hyperactivity Disorder
Ralf W. Dittmann • Esther Cardo • Peter Nagy •
Colleen S. Anderson • Ben Adeyi • Beatriz Caballero •
Paul Hodgkins • Richard Civil • David R. Coghill
Published online: 20 July 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Objectives A secondary objective of this head-to-head
study of lisdexamfetamine dimesylate (LDX) and ato-
moxetine (ATX) was to assess treatment response rates in
children and adolescents with attention-deficit hyperactiv-
ity disorder (ADHD) and an inadequate response to
methylphenidate (MPH). The primary efficacy and safety
outcomes of the study, SPD489-317 (ClinicalTrials.gov
NCT01106430), have been published previously.
Methods In this 9-week, double-blind, active-controlled
study, patients aged 6–17 years with a previous inadequate
response to MPH were randomized (1:1) to dose-optimized
LDX (30, 50 or 70 mg/day) or ATX (patients \70 kg:
0.5–1.2 mg/kg/day, not to exceed 1.4 mg/kg/day; patients
C70 kg: 40, 80 or 100 mg/day). Treatment response was a
secondary efficacy outcome and was predefined as a
reduction from baseline in ADHD Rating Scale IV
(ADHD-RS-IV) total score of at least 25, 30 or 50 %.
Sustained response was predefined as a reduction from
baseline in ADHD-RS-IV total score (C25, C30 or C50 %)
or a Clinical Global Impressions (CGI)–Improvement
(CGI–I) score of 1 or 2 throughout weeks 4–9. CGI–
Severity (CGI–S) scores were also assessed, as an indicator
of remission.
Results A total of 267 patients were enrolled (LDX,
n = 133; ATX, n = 134) and 200 completed the study
(LDX, n = 99; ATX, n = 101). By week 9, significantly
(p \ 0.01) greater proportions of patients receiving LDX
than ATX met the response criteria of a reduction from
baseline in ADHD-RS-IV total score of at least 25 % (90.5
vs. 76.7 %), 30 % (88.1 vs. 73.7 %) or 50 % (73.0
vs. 50.4 %). Sustained response rates were also signifi-
cantly (p \ 0.05) higher among LDX-treated patients
(ADHD-RS-IV C25, 66.1 %; ADHD-RS-IV C30, 61.4 %;
ADHD-RS-IV C50, 41.7 %; CGI–I, 52.0 %) than among
ATX-treated individuals (ADHD-RS-IV C25, 51.1 %;
ADHD-RS-IV C30, 47.4 %; ADHD-RS-IV C50, 23.7 %;
CGI–I, 39.3 %). Finally, by week 9, 60.7 % of patients
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receiving LDX and 46.3 % of those receiving ATX had a
CGI–S score of 1 (normal, not at all ill) or 2 (borderline
mentally ill), and greater proportions of patients in the
LDX group than the ATX group experienced a reduction
from baseline of at least one CGI–S category.
Conclusions Both LDX and ATX treatment were asso-
ciated with high levels of treatment response in children
and adolescents with ADHD and a previous inadequate
response to MPH. However, within the parameters of the
study, LDX was associated with significantly higher
treatment response rates than ATX across all response
criteria examined. In addition, higher proportions of
patients in the LDX group than the ATX group had a CGI–
S score of 1 or 2 by week 9, indicating remission of
symptoms. Both treatments were generally well tolerated,
with safety profiles consistent with those observed in pre-
vious studies.
Key Points
This study presents treatment response rates from a
head-to-head, randomized, double-blind clinical trial
of lisdexamfetamine dimesylate (LDX) and
atomoxetine (ATX) in the treatment of children and
adolescents with attention-deficit hyperactivity
disorder and a previous inadequate response to
methylphenidate therapy
LDX treatment was consistently associated with
statistically significantly higher treatment response
rates than ATX across seven predefined response and
sustained response criteria
Higher proportions of patients receiving LDX than
ATX had a Clinical Global Impressions–Severity
score of 1 (normal, not at all ill) or 2 (borderline
mentally ill) by week 9, indicating remission of
symptoms
1 Introduction
Attention-deficit hyperactivity disorder (ADHD) is a
common neurodevelopmental disorder that is estimated to
affect approximately 5 % of children and adolescents and
3 % of adults worldwide [1–3]. ADHD is characterized by
symptoms of inattention, hyperactivity and/or impulsivity
and is associated with substantial functional impairment
across the lifespan [4, 5]. In addition, ADHD is associated
with reduced health-related quality of life for both patients
and their families [6]. The prodrug stimulant lisdexamfe-
tamine dimesylate (LDX) is an effective treatment for
ADHD in children, adolescents and adults [7–13] and is
currently licensed as a first-line pharmacological therapy
for ADHD in the US, Canada, Brazil and Australia. LDX is
the only long-acting amfetamine formulation available in
Europe, where it is licensed in several countries for the
treatment of ADHD in children aged 6 years and over
when the response to previous methylphenidate (MPH)
therapy is considered clinically inadequate.
Instruments such as the ADHD Rating Scale IV
(ADHD-RS-IV) [14], the Swanson, Nolan and Pelham
version IV (SNAP-IV) scale [15, 16] and the Conners’
Parent Rating Scale-Revised (CPRS-R) [17] may be used
in routine clinical practice to assess symptoms in patients
with ADHD, and changes in mean scores provide evidence
of treatment-related improvements in symptoms. Consid-
erable normative data are available for these scales and
they have all demonstrated good reliability and discrimi-
nant validity in children and adolescents [14, 18]. How-
ever, while informative, changes in mean rating-scale
scores cannot describe the degree of symptom improve-
ment experienced at an individual level. An alternative
approach to assessing the efficacy of a medication in
patients with ADHD is to conduct responder analyses in
order to establish the proportion of patients who show a
clinically relevant response to treatment, where clinical
response is defined a priori. The value of responder anal-
yses when assessing the benefits of pharmacological
treatment options is recognized by the requirement of the
European Medicines Agency (EMA) that clinical response
outcomes be included in all European regulatory trials for
new ADHD medications [19]. Another approach to
exploring clinical benefit at the level of the individual is to
examine the numbers of patients who shift to a less severe
Clinical Global Impressions (CGI)–Severity (CGI–S) cat-
egory as a result of treatment.
The primary efficacy and safety outcomes from a head-
to-head study of LDX and atomoxetine (ATX) in the
treatment of ADHD have been reported (study SPD489-
317; ClinicalTrials.gov identifier: NCT01106430) [20].
This 9-week, double-blind, randomized study was con-
ducted in children and adolescents who had previously
responded inadequately to MPH. In this primary analysis, a
single definition of clinical response was used—a CGI–
Improvement (CGI–I) score of 1 or 2. The time to first
clinical response (the primary study endpoint) was signif-
icantly shorter with LDX treatment than with ATX treat-
ment (median, 12.0 days and 21.0 days, respectively;
p = 0.001), and the proportion of patients with a CGI–I
score of 1 or 2 by the end of the 9-week study was sig-
nificantly higher (81.7 and 63.6 %, respectively;
p = 0.001) [20]. Owing to a lack of consensus within the
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published literature on the most appropriate definition of
clinical response, we now report the results of further
prespecified responder analyses from SPD489-317. These
are based on multiple ADHD-RS-IV and CGI–I criteria
that have been used in previous responder analyses to
assess the efficacy of LDX or ATX treatment [7, 21–27].
We also present shifts from baseline to week 9 in patients’
severity of illness based on CGI–S categories as an indi-
cation of remission.
2 Methods
The study procedures of this international, double-blind,
randomized, parallel-group, phase IIIb trial have been fully
described previously [20]. The trial was conducted in
accordance with current applicable regulations, the Inter-
national Conference on Harmonisation of Good Clinical
Practice, and local ethical and legal requirements. Each
patient’s parent or legally authorized representative pro-
vided written, informed consent, and assent was obtained
from each participant (as applicable) before commencing
study-related procedures. The study was conducted
between June 2010 and July 2012 at 51 centres in nine
countries in Europe and North America.
2.1 Study Population
Children and adolescents (aged 6–17 years) with a primary
diagnosis of ADHD according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR) were eligible for enrolment in the study. Patient
inclusion and exclusion criteria have been described previ-
ously [20]. Key inclusion criteria were an investigator-rated
ADHD-RS-IV total score of 28 or higher at baseline (indi-
cating symptoms of at least moderate severity) and an inade-
quate response to previous or current MPH treatment.
Inadequate response included, but was not limited to, the
presence of some residual ADHD symptoms, inadequate
duration of action, variable symptom control, or the investi-
gator’s judgement that the patient may benefit clinically from
an alternative to MPH. Key exclusion criteria were previous
exposure to amfetamine or ATX, intolerable side effects with
previous MPH treatment, failure to respond to more than one
previous course of one MPH medication (defined as worsened,
unchanged or minimally improved symptoms), previous
treatment with more than one MPH medication (with the
exception of short-term dose titration with immediate-release
MPH [e.g. for B4 weeks] with an adequate response), and
good control of symptoms with acceptable tolerability on
current ADHD medication. Patients with a comorbid psychi-
atric diagnosis with significant symptoms (except for opposi-
tional defiant disorder) were also excluded.
2.2 Study Drug Administration
Patients underwent a 1-week washout period (if applicable)
before baseline (visit 0), after which they were randomized
(1:1) to receive once-daily LDX or ATX. The 9-week,
double-blind, evaluation period comprised 4 weeks of dose
optimization (visits 1–4) and 5 weeks of dose maintenance
(visits 4–9), followed by a 1-week washout period and
safety follow-up (visit 10). Dose optimization was based on
achieving an ‘acceptable response’, defined as a reduction
in ADHD-RS-IV total score of at least 30 % from baseline
and a CGI–I score of 1 or 2, with acceptable tolerability.
Study drugs were to be taken daily, at approximately
0700 h (±2 h), beginning on the day after visit 0. During
the dose-optimization period, doses were increased at
weekly intervals if an acceptable response with the current
dose was not achieved, and one dose reduction was per-
mitted if a patient experienced unacceptable tolerability.
Patients in the LDX group initially received 30 mg/day
and, if required, were titrated to 50 mg/day and then to
70 mg/day. ATX was available in 10, 18, 25, 40 and 60 mg
capsules. In the ATX group, patients who weighed less
than 70 kg at baseline initially received 0.5 mg/kg/day
which was increased to a target dose of 1.2 mg/kg/day (not
to exceed 1.4 mg/kg/day), in accordance with the dose
recommended by the prescribing information for the drug
[28]. Patients in the ATX group who weighed at least 70 kg
at baseline initially received 40 mg/day and, if required,
were titrated to 80 mg/day and then to 100 mg/day. Doses
could not be changed beyond visit 3; participants unable to
tolerate the study drug after this point were to be with-
drawn from the study and complete an early termination
visit. Patients in whom an acceptable response was
achieved were to continue on their optimal dose for the
remainder of the double-blind evaluation period (visits
4–9).
2.3 Efficacy and Safety Assessments
Efficacy was assessed using the investigator-rated CGI–S,
CGI–I [29] and ADHD-RS-IV [14] instruments. The CGI–
S provides an absolute measure of the global impression of
the severity of a patient’s illness on a scale of 1 (normal,
not at all ill) to 7 (among the most severely ill patients),
and was completed at weeks 0, 4 and 9 and/or at early
termination. The CGI–I captures the change in a patient’s
condition compared with baseline on a scale from 1 (very
much improved) to 7 (very much worse), and was com-
pleted at weeks 1–9 and/or at early termination. CGI–I
results were dichotomized into ‘improved’ (score of 1 or 2)
and ‘not improved’ (all other scores). The ADHD-RS-IV is
based on the DSM-IV-TR symptomatology and comprises
18 items that are each rated on a 4-point Likert scale (0–3);
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thus, the total score ranges from 0 to 54, with higher scores
reflecting more severe symptoms than lower scores. The
ADHD-RS-IV was completed at screening, weeks 0–9 and/
or at early termination.
Tolerability and safety measures have been previously
reported, and included treatment-emergent adverse events
(TEAEs), laboratory evaluations, physical examinations
(including body mass), vital signs and electrocardiogram
(ECG) parameters [20]. The Brief Psychiatric Rating Scale
for Children (BPRS-C), the Columbia-Suicide Severity
Rating Scale (C-SSRS) and the Udvalg for Kliniske Un-
dersøgelser Side Effect Rating Scale-Clinician (UKU-
SERS-Clin) were also used to monitor patient tolerability
and safety plus the suitability of individuals to remain in
the study [20].
2.4 Definitions of Response and Sustained Response
The change in ADHD-RS-IV total score from baseline was
used to determine the proportion of patients responding to
treatment according to three separate definitions: reduc-
tions from baseline of at least 25 %, at least 30 % or at
least 50 %. Sustained response based on ADHD-RS-IV
total score was defined as a reduction from baseline of at
least 25, 30 or 50 % that was maintained throughout the
dose-maintenance period (i.e. at weeks 4–9, inclusive).
Sustained response based on CGI–I was defined as an
improved CGI–I score (1 or 2) that was maintained
throughout the same period. These additional analyses for
response and sustained response were defined in the sta-
tistical analysis plan after finalisation of the study protocol
but prior to unblinding of the data.
2.5 Clinical Global Impressions–Severity (CGI-S)
Shifts
CGI–S assessments were carried out at baseline, week 4
and week 9/early termination as an indicator of remission.
Shifts in CGI–S score from baseline to week 9 are pre-
sented as shift tables for individuals who had a valid score
at both visits. Patients with missing baseline or week 9
assessments were excluded from the CGI–S shift tables.
2.6 Statistical Methods
Efficacy analyses were based on the intention-to-treat
principle and were performed using the full analysis set,
defined as all patients who were randomized and received
at least one dose of study drug. Cochran–Mantel–Haenszel
tests stratified by country were used to assess the effect of
treatment on the cumulative proportion of responders at
each of weeks 1–9. For these analyses, the last observation
carried forward (LOCF) approach was applied to data that
were missing owing to early termination or unavailability.
Cochran–Mantel–Haenszel tests stratified by country were
also used to assess the effect of treatment on the proportion
of sustained responders. For these analyses, the approach to
missing data was non-responder imputation, in which
patients with at least one missing assessment (from week 4
to week 9) due to early termination or unavailability were
classified as non-responders. A statistical comparison of
CGI–S shifts associated with LDX and ATX treatment was
not a prespecified analysis and p-values comparing the
effects of each treatment on CGI–S shifts were not
generated.
3 Results
3.1 Patient Disposition and Baseline Characteristics
As described previously [20], 267 patients (LDX,
n = 133; ATX, n = 134) were randomized, 262 (LDX,
n = 127; ATX, n = 135) were included in the full ana-
lysis set (75.2 % of patients were male), and 200
(74.9 %) completed the study (LDX, n = 99; ATX,
n = 101). Baseline demographics and disease character-
istics were similar between treatment groups [20]. Mean
(standard deviation [SD]) baseline ADHD-RS-IV total
scores were similar in both treatment groups (LDX, 42.6
[6.14], range 28–54; ATX, 41.9 [6.70], range 28–53), and
mean (SD) CGI–S scores were also similar in both
groups (LDX, 5.0 [0.80], range 3–7; ATX, 5.0 [0.73],
range 4–7). The mean (SD) optimal dose (which was the
dose that was dispensed at visit 4) for patients who
received LDX during the dose-maintenance phase was
52.5 mg/day (16.10) and was 40.2 mg/day (20.05) for
patients who received ATX.
3.2 Attention-Deficit Hyperactivity Disorder Rating
Scale IV Responders
For all three definitions of response based on improvements
in ADHD-RS-IV, the proportion of patients who responded
to treatment was statistically significantly higher in the
LDX-treated group than in the ATX-treated group at each
weekly visit (p \ 0.05 for all response criteria) (Fig. 1).
Increases in response rates over time were observed in both
treatment groups, primarily during the dose optimization
phase. By week 9, the proportions of patients (95 % con-
fidence interval) with reductions from baseline in ADHD-
RS-IV total score of at least 25, 30 or 50 % were 90.5 %
(85.4–95.6), 88.1 % (82.4–93.7) and 73.0 % (65.3–80.8) in
the LDX group, and 76.7 % (69.5–83.9), 73.7 %
(66.2–81.2) and 50.4 % (41.9–58.9) in the ATX group,
respectively.
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3.3 Sustained Responders
The proportion of patients who responded to treatment
throughout weeks 4–9 was statistically significantly higher in
the LDX group than in the ATX group for all four ADHD-RS-
IV and CGI–I definitions of sustained response (p \0.05 for all
comparisons) (Fig. 2). The proportions of sustained responders
decreased with increasing ADHD-RS-IV thresholds. The
proportions of patients meeting the CGI–I response criteria of 1
or 2 was between the proportions experiencing a C30 and
C50 % reduction in ADHD-RS-IV total score.
3.4 CGI–S Shifts
An analysis of shifts in CGI–S scores from baseline to visit
9 is shown in Table 1, based on observed values for
Fig. 1 Proportion of patients
classified as responders using
definitions based on a
(a) C25 %, (b) C30 % or
(c) C50 % reduction in ADHD-
RS-IV total score [14] from
baseline (last observation
carried forward). *p \ 0.05,
**p \ 0.01, ***p \ 0.001 LDX
versus ATX (Cochran–Mantel–
Haenszel test stratified by
country). Error bars show 95 %
confidence intervals.
Percentages are based on the
number of patients in each
treatment group at the indicated
study visit. ADHD-RS-IV
Attention Deficit Hyperactivity
Disorder Rating Scale IV, ATX
atomoxetine, LDX
lisdexamfetamine dimesylate
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individuals with a valid week 9 CGI–S score (LDX, 95/127
patients [74.8 %]; ATX, 97/135 patients [71.9 %]). At
week 9, no patients from either treatment group had shifted
to a more severe category of illness than that observed at
baseline. In the LDX group, five patients remained in their
baseline CGI–S category at week 9, ten patients improved
by one category and 80 patients improved by more than
one category. In the ATX group, 13 patients remained in
their baseline CGI–S category, 14 patients improved by
one category and 70 patients improved by more than one
category. At week 9, 13/20 patients in the LDX group and
9/24 patients in the ATX group had shifted from the most
severe CGI–S categories of 6 (severely ill) or 7 (among the
most extremely ill) to a CGI–S score of 1 (normal, not at all
ill) or 2 (borderline mentally ill). A total of five patients
(LDX, n = 1; ATX, n = 4) remained in the two most
severe CGI–S categories at week 9.
Using the LOCF approach, 71/117 patients (60.7 %) in
the LDX group and 57/123 patients (46.3 %) in the ATX
group had a CGI–S score of 1 or 2 by week 9, indicating
remission.
4 Discussion
In these analyses of data from the first head-to-head, ran-
domized, controlled trial of LDX and ATX, LDX treatment
was consistently associated with statistically significantly
higher rates of clinical response than ATX treatment in
children and adolescents with ADHD and an inadequate
response to MPH, irrespective of the ADHD-RS-IV or
CGI–I criteria used to define response (p \ 0.01 for all
comparisons). In addition, the proportions of patients with
a sustained response, defined as those who met response
criteria throughout weeks 4–9, were also statistically sig-
nificantly higher among patients receiving LDX than
among those receiving ATX (p \ 0.05 for all compari-
sons). Finally, after 9 weeks of treatment, the proportion of
patients who had low levels of disease severity (CGI–S
score of 1 or 2) was numerically higher among individuals
receiving LDX than among those receiving ATX.
The present responder data, and those previously
reported for this study which found that a significantly
greater proportion of patients receiving LDX (81.7 %) than
ATX (63.6 %) achieved a CGI–I score of 1 or 2 by visit 9
(p \ 0.01) [20], are generally consistent with those
observed in previous studies of LDX and ATX, despite
differences in study designs and patient populations [7, 20–
23, 25–27]. Several other clinical trials have found LDX to
be associated with significantly higher proportions of
treatment responders than placebo irrespective of the age of
the patients [7, 20, 23, 25, 27]. When clinical response was
defined as at least a 30 % reduction from baseline in
ADHD-RS-IV total score, approximately 65 % of adult
patients receiving LDX were categorized as responders
after 4 weeks of treatment, compared with approximately
35 % of those receiving placebo [7]. Three LDX studies
used the combined response criteria of at least a 30 %
reduction from baseline in ADHD-RS-IV total score and a
CGI–I score of 1 or 2. First, a US-based study in children
with ADHD found that 79.3 % of patients treated with
LDX responded, compared with 29.2 % of those receiving
placebo [25]. Among the subgroup of study participants
who had previously experienced an inadequate response to
Fig. 2 Patients classified as sustained responders (weeks 4–9) using
definitions based on (a) ADHD-RS-IV total scores or (b) CGI–I
scores. *p \ 0.05, **p \ 0.01 LDX versus ATX (Cochran–Mantel–
Haenszel test stratified by country). Sustained response was defined as
the indicated percentage reduction in ADHD-RS-IV total score from
baseline or an improved CGI–I score (1 or 2) at all study visits in
weeks 4–9. Error bars show 95 % confidence intervals. Data are
based on non-responder imputation. ADHD-RS-IV Attention Deficit
Hyperactivity Disorder Rating Scale IV, ATX atomoxetine, CGI–I
Clinical Global Impressions–Improvement, LDX lisdexamfetamine
dimesylate
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MPH treatment, response rates for LDX (78.9 %) were
similar to those in the overall study population and to the
responder rates observed for LDX in the present study,
which was also conducted in patients with a history of
inadequate response to MPH treatment [20, 25]. Second,
clinical response was examined post hoc in a 12-month,
open-label LDX study in adults with ADHD, categorized
according to their baseline CGI–S score (4, 5 or C6) [23].
This study revealed numerically higher (a statistical anal-
yses was not performed) proportions of clinical responders
Table 1 Observed shifts in CGI–S score from baseline to week 9 (N = 262)
LDX (n=127) Week 9 score
Baseline score 1
(Normal, 
not at all 
ill)
2
(Borderline 
mentally 
ill)
3
(Mildly ill)
4
(Moderately 
ill)
5
(Markedly 
ill)
6
(Severely 
ill)
7
(Among 
the most 
extremely 
ill)
All
1 (Normal, not at all ill) 0 0 0 0 0 0 0 0
2 (Borderline mentally ill) 0 0 0 0 0 0 0 0
3 (Mildly ill) 0 0 0 0 0 0 0 0
4 (Moderately ill) 5 13 7 0 0 0 0 25
5 (Markedly ill) 15 17 11 3 4 0 0 50
6 (Severely ill) 3 6 4 1 0 1 0 15
7 (Among the most extremely ill) 2 2 0 0 1 0 0 5
All 25 38 22 4 5 1 0 95
ATX (n=135) Week 9 score
Baseline score 1
(Normal, 
not at all 
ill)
2
(Borderline 
mentally 
ill)
3
(Mildly ill)
4
(Moderately 
ill)
5
(Markedly 
ill)
6
(Severely 
ill)
7
(Among 
the most 
extremely 
ill)
All
1 (Normal, not at all ill) 0 0 0 0 0 0 0 0
2 (Borderline mentally ill) 0 0 0 0 0 0 0 0
3 (Mildly ill) 0 0 0 0 0 0 0 0
4 (Moderately ill) 5 8 8 3 0 0 0 24
5 (Markedly ill) 11 19 8 5 6 0 0 49
6 (Severely ill) 5 4 6 4 1 3 0 23
7 (Among the most extremely ill) 0 0 0 0 0 0 1 1
All 21 31 22 12 7 3 1 97
Data are based on observed values for patients with a CGI–S score at week 9. Dark grey shading indicates patients who shifted to a lower CGI–S
category from baseline to week 9. Light grey shading indicates patients who remained in their baseline CGI–S category at week 9
ATX atomoxetine, CGI–S Clinical Global Impressions–Severity, LDX lisdexamfetamine dimesylate
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among individuals with more severe baseline illness than
those with less severe baseline illness (CGI–S of 4, 78.9 %;
CGI–S of 5, 83.5 %; CGI–S of C6, 88.4 %) [23]. In
addition, 71.3 % of patients had at least a 50 % reduction
from baseline in ADHD-RS-IV total score [23], a value
which, despite differences in study design and population,
is very similar to the results of the present 9-week, double-
blind, paediatric study (LDX, 73.0 %). Third, 74.2 % of
patients receiving LDX compared with 10.7 % of those
receiving placebo met the combined response criteria in a
7-week European regulatory trial in children and adoles-
cents with ADHD, and 78.0 and 14.4 %, respectively, had
a CGI–I score of 1 or 2 at endpoint [27]. As required by the
EMA, this last study included an active comparator treat-
ment (osmotic-release oral system MPH; OROS-MPH) to
validate the study design and to contextualize the results. A
post hoc comparison indicated that the proportion of
patients who responded to LDX was significantly
(p \ 0.05) larger than the proportion who responded to
OROS-MPH (combined criteria, 55.9 %; CGI–I of 1 or 2,
60.6 %) [27]. Given that this study was neither designed
nor powered to provide a direct comparison between
treatments, these findings should be considered as pre-
liminary. The results of ongoing parallel-group studies in
adolescents (ClinicalTrials.gov identifiers: NCT01552915
and NCT01552902) will provide definitive evidence of the
relative benefits of LDX and MPH.
The results of the present responder analyses are also
broadly consistent with those of previous studies of ATX.
Pooled data from six randomized controlled trials of
6–9 weeks in duration in children and adolescents with
ADHD (N = 1,069) revealed that 60 % of patients had at
least a 25 % reduction from baseline in ADHD-RS-IV total
score, and 47 % had a decrease of at least 40 % [21].
Another pooled analysis combined data from three Cana-
dian open-label studies in children and predicted that 75 %
of patients would achieve at least a 25 % reduction from
baseline in ADHD-RS-IV total score after 7.2 weeks of
ATX treatment [22]. This finding is very similar to the
results of the present study. A meta-analysis indicated that
the proportions of patients with a clinically relevant
response to ATX were not significantly different from the
proportions responding to MPH treatment, when response
was defined as a reduction of at least 40 % (53.6 vs.
54.4 %) or at least 25 % (69.0 vs. 70.0 %) from baseline in
ADHD-RS-IV total score, or as achieving a CGI–S score of
1 or 2 (18.2 vs. 24.3 %) [24]. However, it should be noted
that only one of the seven studies included in the meta-
analysis compared ATX with a long-acting MPH formu-
lation (OROS-MPH), and in that study the clinical response
to OROS-MPH was superior to that of ATX [26].
Responder analyses allow the degree of clinically
meaningful symptom improvement in individual patients to
be established. Despite the recognized benefits of respon-
der analyses, a consensus has not been reached on the most
appropriate criteria to use when assessing clinical response
to ADHD medication and, as described above, various
response criteria have been used in studies assessing the
efficacy of LDX and ATX. In the present study, increasing
the degree of change in ADHD-RS-IV total score required
for response resulted in a decrease in responder rates.
Response rates based on a CGI–I score of 1 or 2 [20]
appeared to correspond with an ADHD-RS-IV total score
reduction of between 30 and 50 %. This is slightly lower
than findings from a previous analysis of two LDX studies
in paediatric populations, where reductions from baseline
in ADHD-RS-IV total score of 80, 52 and 27 % correspond
to CGI–I scores of 1 (very much improved), 2 (much
improved) and 3 (minimally improved), respectively, per-
haps due to differences in study design. The authors of that
study suggested that on the basis of these results, a
reduction in ADHD-RS-IV total score of at least 50 %
should be used to define clinical response [30].
Despite a continued lack of consensus on the appropriate
threshold to use when defining a clinically relevant
response to treatment, it was clear in the present head-to-
head study that the relative benefits of LDX compared with
ATX treatment remained similar irrespective of which
response criterion was used. This finding is consistent with
a meta-analysis of 32 clinical trials that concluded that both
short- and long-acting psychostimulants were significantly
more effective than non-stimulants [31]. The present study
also examined sustained response, revealing that a signif-
icantly larger proportion of patients receiving LDX than
those receiving ATX met continued response criteria
throughout weeks 4–9. This is the first study of either LDX
or ATX to determine sustained response, an obviously
desirable outcome in the clinical setting.
A criticism of responder analyses is that they do not take
into account patients’ baseline disease severity. Therefore,
individuals with severe baseline symptoms may meet
clinical response criteria at study endpoint despite signifi-
cant residual symptoms and/or impairment. To address
this, some studies have assessed the proportions of patients
whose symptoms reduce to below a defined ‘remission’
threshold. However, a consensus has still to be reached on
the most appropriate criterion to be used to define remis-
sion. In previous studies of LDX and ATX, an ADHD-RS-
IV score of 18 or less [22, 23, 25] or a CGI–S score of 2 or
less [22, 32] were used to define remission. In the present
study, CGI–S scores (based on LOCF) revealed that
60.7 % of patients receiving LDX and 46.3 % of those
receiving ATX had a CGI–S score of 2 or less by week 9.
These values are consistent with those observed in a pooled
analysis of three open-label studies which concluded that
the probability of children achieving a CGI–S score of 2 or
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less was 8 % after 4 weeks of ATX treatment and 47 %
after 12 weeks of ATX treatment [22].
Safety outcomes from this study have previously been
published [20]. In summary, similar proportions of patients
in both treatment groups reported TEAEs (LDX, 71.9 %;
ATX, 70.9 %). In addition, changes in mean vital signs and
ECG parameters, and in the frequency of outliers and
potentially clinically important observations, were gener-
ally similar between treatment groups [20].
The strengths of this study include its double-blind, ran-
domized, parallel-group, dose-optimized design, and the
large international patient population. In addition, the results
are particularly pertinent in Europe, given the recent
approval of LDX in several European countries for the
treatment of children and adolescents in whom previous
MPH treatment was clinically inadequate; under these cir-
cumstances, the choice of medication in most countries will
be between LDX and ATX. It is unclear whether this highly
selected patient population, who were required to meet
multiple inclusion and exclusion criteria relating to their
previous exposure and/or response to ADHD medication,
would have been more likely to respond to one treatment arm
than the other. However, similarities in the results of this and
other studies suggest that these inclusion/exclusion criteria
do not unduly favour either treatment arm. In addition, the
details of the study design, as described in the paediatric
investigation plan, were agreed with the EMA. A potential
limitation of this study is the 9-week duration which might
have limited the potential benefits of ATX. Indeed, a meta-
analysis of pooled data from ATX studies (N = 601) indi-
cated that the response to ATX continued to grow for as long
as 12 weeks, although most of the improvement occurred
during the first 4 weeks and any subsequent further
improvement occurred in conjunction with increasing mean
ATX dose [33]. There is also evidence to suggest that higher
doses of ATX than used in the present study and recom-
mended in the product’s prescribing information (up to
1.8 mg/kg) may result in higher levels of efficacy of ATX
[34, 35]. In addition, there is some evidence that ATX is more
effective when administered twice daily than once daily, as
used in the present study [34]. Finally, although there are
only three available LDX doses, a greater variety of doses are
available for ATX. Therefore, the length of the dose-opti-
mization period of the study may not have permitted all ATX
doses to be fully explored, which may have affected patient
outcomes in the ATX treatment group.
5 Conclusions
Response rates were significantly higher in the LDX
treatment group than in the ATX group among children
and adolescents with at least moderately symptomatic
ADHD and a previous inadequate response to MPH
therapy, within the parameters of the study. The superior
efficacy of LDX over ATX was maintained irrespective of
the criteria used to determine a clinically relevant
response to treatment.
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